Ionis Pharmaceuticals has pulled the plug on an early investigational treatment for Alzheimer’s disease in people wit...
Ionis Pharmaceuticals has discontinued an early investigational Alzheimer's treatment in people with Down syndrome, representing another setback for a high-risk, underserved patient group.
Why it mattersIonis' abandonment of an early Alzheimer's program in Down syndrome should prompt funders to reallocate investments.